Join to View Full Profile
Nci Nih10 Center Dr, Room 3s235Bethesda, MD 20892
Phone+1 301-480-8076
Fax+1 301-480-8089
Dr. Stetler-Stevenson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematopathology, 1988 - 1992
McGaw Medical Center of Northwestern UniversityResidency, Pathology-Anatomic and Clinical, 1985 - 1987- Northwestern University The Feinberg School of MedicineClass of 1984
Certifications & Licensure
MD State Medical License 1987 - 2025
American Board of Pathology Anatomic Pathology
Publications & Presentations
PubMed
- 2 citationsPotentiating CD20 monoclonal antibody therapy by targeting complement C3 fragments covalently deposited on lymphoma cells.Sivasubramanian Baskar, Haiyong Peng, Erika M Gaglione, Elizabeth J Carstens, Margaret A Lindorfer
Blood. 2025-03-20 - 25 citationsEVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma.Ola Landgren, Thomas J Prior, Tara Masterson, Christoph Heuck, Orlando F Bueno
Blood. 2024-07-25 - 3 citationsStandardization of flow cytometric detection of antigen expression.Linhua Tian, Aaron R Nelson, Tyler Lowe, Linda Weaver, Constance Yuan
Cytometry. Part B, Clinical Cytometry. 2024-01-01
Abstracts/Posters
- Long Term Follow-up of a Phase II Study of Cladribine with Concurrent Rituximab in Patients with Hairy Cell Leukemia VariantMaryalice Stetler-Stevenson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain Induce Remissions ...Maryalice Stetler-Stevenson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Phase I/II Study of Lenalidomide Combined with DA-EPOCH and Rituximab (DA-EPOCH-R2) in Primary Effusion Lymphoma in Patients with or without HIVMaryalice Stetler-Stevenson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term D...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Molecular Remissions with Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox Are Associated with Improved Complete Remission Durations during Phase I and III Testing2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Molecular Remissions with Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox Are Associated with Improved Complete Remission Durations during Phase I and III Testing2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Minimal Disease, Maximum BenefitAugust 12th, 2024
High Remission Rate from Anti-CD22 CAR T-cell Therapy in Pediatric ALLDecember 5th, 2016
Grant Support
- Flow Cytometric Evaluation Of BiomarkersNational Cancer Institute2010–2011
- Flow Cytometric Detection Of Malignant Cells In Body FluidsNational Cancer Institute2010–2011
- Flow Cytometric Analysis Of Benign And Malignant TumorsNational Cancer Institute2010–2011
- Flow Cytometric Analysis Of Benign And Malignant TumorsDivision Of Clinical Sciences - Nci2009
- Flow Cytometric Evaluation Of BiomarkersDivision Of Basic Sciences - Nci2009
- Flow Cytometric Detection Of Malignant Cells In Body FluidsDivision Of Basic Sciences - Nci2009
- Flow Cytometric Evaluation Of BiomarkersNational Cancer Institute2008
- Flow Cytometric Analysis Of Benign And Malignant TumorsNational Cancer Institute2007–2008
- THR Role Of TIMP1 In B Cell Differentiation And SurvivalDivision Of Clinical Sciences - Nci2004–2006
- Flow Cytometric Analysis Of Benign And Malignant TumorsDivision Of Clinical Sciences - Nci1996–2006
- Role Of TIMP1 In B Cell Differentiation And SurvivalDivision Of Clinical Sciences - Nci2003
- TIMP-1 Expression By Normal/Neoplastic LymphocytesDivision Of Clinical Sciences - Nci2001
- TIMP-1 Expression By Normal Lymphocytes &In Lymphoid NEDivision Of Clinical Sciences - Nci2000
- Flow Cytometric Analysis Of Benign &Malignant TumorsDivision Of Clinical Sciences - Nci2000
- TIMP 1 Expression By Normal Lymphocytes And In Lymphoid NeoplasmsDivision Of Clinical Sciences - Nci1997–1998
- Phase II Evaluation Of Topotecan In Melanoma An Renal CelllasmsDivision Of Clinical Sciences - Nci1996
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
